Browse Drug Recalls
16 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 16 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 16 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Apr 6, 2018 | Triamterene and Hydrochlorothiazide Tablets, USP, 75 mg/50 mg, 500-count bott... | Cross Contamination With Other Products: presence of unrelated ingredients (i.e. traces of Lisino... | Class III | Sandoz Incorporated |
| Jun 16, 2017 | Amitriptyline HCl Tablets, USP 25 mg, Packaged in a)100-count bottles (NDC 07... | Cross Contamination With Other Product: Imipramine | Class III | Sandoz Incorporated |
| Dec 22, 2016 | Nadolol Tablets, USP, 40mg, packaged in 1000-count bottle, Rx Only, Manufactu... | Failed dissolution specification: recalled due to an out of specification dissolution result of 4... | Class II | Sandoz Incorporated |
| Dec 5, 2014 | Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sand... | Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an i... | Class III | Sandoz Incorporated |
| Jul 25, 2014 | Alprazolam Tablets, USP, 0.25mg, Rx only, 1000 tablets, Sandoz Inc., Princeto... | Presence of Foreign Substance; tablets may contain stainless steel metal particulates | Class II | Sandoz Incorporated |
| Oct 22, 2013 | Tacrolimus Capsules, USP, 0.5 mg, 100 capsules/bottle, Rx only, Manufactured ... | Cross Contamination with Other Products: findings of carryover of trace amounts of a previously m... | Class II | Sandoz Incorporated |
| Sep 25, 2013 | Hydroxychloroquine Sulfate Tablets, USP, 200 mg, Rx Only, 100 Tablets per bot... | Failed Tablet/Capsule Specifications: Sandoz is recalling one lot of Hydroxychloroquine Sulfate T... | Class III | Sandoz Incorporated |
| Aug 7, 2013 | Introvale (levonorgestrel and ethinyl estradiol) tablets, USP, 0.15 mg/0.03 m... | Contraceptive tablets out of sequence: Contraceptive tablets out of sequence: Introvale (levonorg... | Class III | Sandoz Incorporated |
| Jun 21, 2013 | Estarylla (Norgestimate and Ethinyl Estradiol) Tablets. USP, 0.25mg/0.035mg, ... | Contraceptive Tablets out of Sequence: A placebo tablet was found in a row of active tablets. | Class II | Sandoz Incorporated |
| May 30, 2013 | Cefazolin, injection, 1 gram per vial, 25 vials per box, sterile, Rx only, si... | Lack of Assurance of Sterility: Sandoz Inc is recalling Cefazolin for Injection, USP 1 gm vials, ... | Class II | Sandoz Incorporated |
| May 20, 2013 | Methotrexate Injection, USP, Preservative-Free, 1 g/40 mL (25 mg/mL), 40 mL S... | Presence of Particulate Matter: Found during examination of retention samples. | Class I | Sandoz Incorporated |
| Apr 18, 2013 | Amoxicillin Capsules USP 500 mg, Manufactured in Austria by Sandoz GmbH for S... | Presence of Foreign Substance, Sandoz is recalling certain lots of Amoxicillin Capsules, USP 500 ... | Class II | Sandoz Incorporated |
| Jan 22, 2013 | Syeda (drospirenone and ethinyl estradiol), 3 mg/0.03 mg, 3 x 28 tablet blist... | Tablet/Capsule Imprinted with Wrong ID; a portion of the tablets could contain the incorrect debo... | Class III | Sandoz Incorporated |
| Sep 20, 2012 | Children's Cetirizine HCl Chewable Tablets 5 mg, 30 count blister pack, Manuf... | Impurity/Degradation; exceeded impurity specification at the 8 and 15 month time points (betacycl... | Class III | Sandoz Incorporated |
| Sep 12, 2012 | Pramipexole Dihydrochloride Tablets, 0.25 mg, 90-count tablets per bottle, Rx... | Impurities/Degradation Products: An out of specification result for a known impurity of the produ... | Class III | Sandoz Incorporated |
| Sep 12, 2012 | Pramipexole Dihydrochloride Tablets, 0.125 mg, 90-count tablets per bottle, R... | Impurities/Degradation Products: An out of specification result for a known impurity of the produ... | Class III | Sandoz Incorporated |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.